Table 1. Clinical Data and Outcome .... | American Society of Hematology

Table 1.

Clinical Data and Outcome

	Sex/Age	Isotype	Stage	Duration Standard Therapy (months)	CD34/kg Collected (×10⁶)	CD34⁺ Thy₁⁺/kg per Transplant (×10⁵)	Viability Postthawing (%)	Response	Outcome
1	M/54	IgGλ	IIIB	4	31.4	3.9	82	NR	Died, MOF
2	M/52	NS	IIIA	7	24.4	3.7	79	CR	Died, ARDS
3	M/55	IgGκ	IIIA	5	55.8	8.5	86	NR	Alive, stable disease 20 months+
4	M/42	−κ	IIIB	9	5.4	—	—	PR	Failure to collect
5	M/58	IgAκ	IIIA	2	38.1	5.7	86	NR	Alive, stable disease 19 months+
6	M/57	IgAλ	IIA	2	27.6	4.6	75	NR	Alive, stable disease 18 months+
7	M/30	NS	IIIA	3	30.5	3.6	93	CR	Alive, relapse 7 months
8	F/49	IgGκ	IIA	6	9.2	3.9	89	NR	Alive, progression 10 months
9	M/47	IgGκ	IIA	3	84.7	3.6	88	PR	Alive, progression 11 months
10	M/53	IgGλ	IIA	3	17.5	3.7	51	NR	Alive, stable disease 16 months+

	Sex/Age	Isotype	Stage	Duration Standard Therapy (months)	CD34/kg Collected (×10⁶)	CD34⁺ Thy₁⁺/kg per Transplant (×10⁵)	Viability Postthawing (%)	Response	Outcome
1	M/54	IgGλ	IIIB	4	31.4	3.9	82	NR	Died, MOF
2	M/52	NS	IIIA	7	24.4	3.7	79	CR	Died, ARDS
3	M/55	IgGκ	IIIA	5	55.8	8.5	86	NR	Alive, stable disease 20 months+
4	M/42	−κ	IIIB	9	5.4	—	—	PR	Failure to collect
5	M/58	IgAκ	IIIA	2	38.1	5.7	86	NR	Alive, stable disease 19 months+
6	M/57	IgAλ	IIA	2	27.6	4.6	75	NR	Alive, stable disease 18 months+
7	M/30	NS	IIIA	3	30.5	3.6	93	CR	Alive, relapse 7 months
8	F/49	IgGκ	IIA	6	9.2	3.9	89	NR	Alive, progression 10 months
9	M/47	IgGκ	IIA	3	84.7	3.6	88	PR	Alive, progression 11 months
10	M/53	IgGλ	IIA	3	17.5	3.7	51	NR	Alive, stable disease 16 months+

Abbreviations: NS, nonsecretory; MOF, multiorgan failure.